Neuland Laboratories Q1 FY26 results (Apr–Jun 2025) and concall

Neuland Labs reported a challenging Q1 FY26, with a significant 32.4% YoY revenue decline due to the lumpy nature of order flows in its CMS and GDS segments. This top-line weakness led to severe operating deleverage, causing a sharp fall in profitability. Despite the poor start, management maintained its full-year growth outlook, banking on the commercialization of a new CMS molecule and the ramp-up of its new Unit 3 production block in the latter half of FY26. The focus remains on strategic investments in peptides and capacity expansion to drive future growth.